Executive Vice President and Chief Administrative Officer · TANDEM DIABETES CARE INC (TNDM)

Susan Morrison

A named executive officer of TANDEM DIABETES CARE in every fiscal year CompBrief holds from FY2019 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,005,471

Salary $450,203Stock awards $1,307,627

FY2022: $1,767,407

4th of 6 named executive officers at Tandem Diabetes Care by FY2024 total.

6 named officers on file for TANDEM DIABETES CARE, FY2024

Susan Morrison’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 10 equity grants, each cited to its filing
  • TNDM’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TANDEM DIABETES CARE’s whole pay program stands against its peers

  • TANDEM DIABETES CARE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TNDM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Susan Morrison’s full pay file as a PDF — free

More than this page: up to 10 years of Susan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Susan Morrison compensation by year

TANDEM DIABETES CARE Summary Compensation Table · all 5 fiscal years held
In US dollars, as TANDEM DIABETES CARE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2024
Salary$400,000$412,000$424,360$437,091$450,203
Bonus$0$25,532$0$0$0
Stock awards$0$535,539$424,312$732,050$1,307,627
Option awards$4,621,634$803,352$424,335$360,598$0
Non-equity incentive$368,110$178,726$339,403$132,628$239,863
Pension and deferred compensation$0$0$0$0$0
All other$497$608$585$105,040$7,778
Total$5,390,241$1,955,757$1,612,995$1,767,407$2,005,471

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TANDEM DIABETES CARE INC DEF 14A filed April 8, 2025, accession 0001438133-25-000058, and prior-year filings.

How this page was built: the TANDEM DIABETES CARE INC filed document, accession 0001438133-25-000058. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

$5.4M
$2.0M
$1.6M
$1.8M
$2.0M
FY19
FY20
FY21
FY22
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,161$474,059—
PSU13,160$474,023—
RSU9,019$324,864—
PSU8,883$319,966—
PSU5,523$198,938—
PSU1,380$49,708—
RSU948$34,147—
RSU325$11,707—
Option827—$81.63
Option1,187—$65.28

Per the Outstanding Equity Awards at Fiscal Year-End table in TANDEM DIABETES CARE INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

56 Form 4 lines since the FY2024 proxy (filed April 8, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-15Exercise or conversion derivative—1,097$0.002,193
2026-11-15Tax withholding—314$20.0753,571
2026-11-15Exercise or conversion—1,731$0.0055,302
2026-11-15Tax withholding—496$20.0754,806
2026-11-15Exercise or conversion—1,097$0.0053,885
2026-11-15Exercise or conversion derivative—1,731$0.0010,384
2026-08-15Exercise or conversion—1,097$0.0051,867
2026-08-15Exercise or conversion derivative—1,730$0.0012,115

The 8 most recent of 56 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments TANDEM DIABETES CARE discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and resignation for good reason$1,080,487$1,931,320—$3,011,807
Change in control and involuntary termination$1,080,487$1,931,320—$3,011,807

Per the Potential Payments Upon Termination or Change in Control table in TANDEM DIABETES CARE INC's FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

TANDEM DIABETES CARE’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
John SheridanPresident and Chief Executive Officer$8,526,238
Leigh VossellerExecutive Vice President, Chief Financial Officer and Treasurer$2,480,081
Jean-Claude KyrillosExecutive Vice President and Chief Operating Officer$2,431,600
Susan Morrison · this pageExecutive Vice President and Chief Administrative Officer$2,005,471
Elizabeth GasserExecutive Vice President and Chief Strategy and Product Officer$2,005,471
Mark NovaraExecutive Vice President and Chief Commercial Officer$802,745

The full TANDEM DIABETES CARE compensation record

free company brief

This page is one person within TANDEM DIABETES CARE's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TANDEM DIABETES CARE proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TANDEM DIABETES CARE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Susan Morrison's compensation dossier · One-time report. No refunds.